NL-OMON51775已完成不适用
A Phase I Study to Assess Biodistribution of 89Zr-CB307 in PSMA+ and PSMA-Tumour Lesions - CB307 Radio-labeled sub-study
Cresendo Biologics Ltd0 个研究点目标入组 12 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Is capable of understanding the written informed consent form (ICF),
- •provides signed and witness informed consent and agrees to comply with protocol
- •requirements
- •2. Is aged at least 18 years at the time of signing the ICF
- •3. Has a documented, histologically-confirmed diagnosis of advanced or
- •metastatic solid tumours
- •See protocol page 26 for the full list of inclusion criteria)
- •Note: Subject must qualify for the main study and must have met the relevant
- •inclusion and exclusion criteria and signed the ICF for the main study (see
- •also section J)
排除标准
- •1. Has evidence of autoimmune or significant, uncontrolled concomitant diseases
- •that could affect compliance with the protocol or interpretation of the results
- •2. Has discontinued from anti-cytotoxic lymphocyte-associated protein 4,
- •anti-programmed cell death protein 1, or anti-programmed cell death ligand 1
- •antibody because of intolerable toxicity according to the investigator*s
- •assessment.
- •3. Has brain metastasis, including leptomeningeal metastasis or a primary brain
研究者
相似试验
招募中
1 期
Safety, tolerability, and biodistribution of [89Zr]Zr-DFO-APAC (Phase 0) in subjects with peripheral arterial occlusive disease / critical limb ischemia (PAOD/CLI) and healthy volunteers – an open label PET study (CHASE-study)Critical limb ischemia, Peripheral arterial occlusive diseaseMedDRA version: 21.1Level: LLTClassification code: 10058072Term: Critical limb ischaemia Class: 10047065MedDRA version: 21.1Level: PTClassification code: 10062585Term: Peripheral arterial occlusive disease Class: 100000004866CTIS2023-505287-11-01Aplagon Oy10
进行中（未招募）
1 期
ptake of 89Zr-labeled ipilimumab measured with PET-scan in patients who are treated with ipilimumabMedDRA version: 21.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Advanced melanomaEUCTR2012-003616-31-NLVU medical center24
招募中
不适用
ptake and biodistribution of 89Zirconium-labeled ipilimumab in ipilimumab treated patients with metastatic melanomamelanoma10040900NL-OMON53144Vrije Universiteit Medisch Centrum22
尚未招募
不适用
Opname en biodistributie van 89Zirconium gelabeld ipilimumab in melanoompatiënten die behandeld worden met ipilimumabNL-OMON27886VU University Medical Center29
招募中
早期 1 期
Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)Peripheral Arterial Occlusive DiseaseCritical Limb IschemiaNCT06204237Aplagon Oy10